Focus: Rhythm Pharmaceuticals is a public biotech focused on peptide therapeutics for neurology, with a peak-stage product (IMCIVREE/setmelanotide) and emerging pipeline in hypothalamic obesity. The company operates at 201–500 employees and generated $77M revenue in FY2025.
Profile data last refreshed 7h ago · AI intelligence enriched 1mo ago
Growing — net +12 jobs in 30d
32 jobs added vs 20 removed. Steady team buildout.
Rhythm offers growth-stage opportunity in a focused peptide franchise, but financial model is pre-profitability and pipeline-thin; best for candidates seeking high R&D intensity with IPO-stage upside and tolerance for restructuring risk.
Help build intelligence for Rhythm Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Rhythm Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
FDA-approved melanocortin 4 receptor agonist and company's sole marketed product; 9+ years of exclusivity remaining provides revenue runway but creates single-product risk.
LG Chem's obesity drug deal with Rhythm grows to $855 million - Korea Biomedical Review
LG Chem's obesity drug deal with Rhythm grows to $855 million Korea Biomedical Review
LG Chem Expands Obesity Drug Licensing Deal with Rhythm Pharmaceuticals to $855 Million - Korea IT Times
LG Chem Expands Obesity Drug Licensing Deal with Rhythm Pharmaceuticals to $855 Million Korea IT Times
Rhythm Pharmaceuticals (Nasdaq:RYTM) - Stock Analysis - Simply Wall St
Rhythm Pharmaceuticals (Nasdaq:RYTM) - Stock Analysis Simply Wall St
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Japan Drug Launch - Simply Wall St
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Japan Drug Launch Simply Wall St
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity - Yahoo Finance
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity Yahoo Finance
Insider lines up multimillion-dollar stock sale at Rhythm Pharmaceuticals (NASDAQ: RYTM) - Stock Titan
Insider lines up multimillion-dollar stock sale at Rhythm Pharmaceuticals (NASDAQ: RYTM) Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Impact of setmelanotide on metabolic syndrome risk in patients with proopiomelanocortin or leptin receptor deficiencies.
Measuring Hunger Severity in Rare MC4R Pathway Diseases: Development and Psychometric Evaluation of the Most Hunger Item.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo